Trial Search Results
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
This retrospective, multinational, single-arm study will be conducted in at least 8 sites. An interim analysis will be conducted with data from 100 patients with up to 10 well defined HCC tumor(s) and with at least one tumor ≥3 cm. Normal tissue absorbed dose using pre-procedural 99mTc MAA SPECT or SPECT/CT imaging will be measured to allow the mean absorbed normal tissue dose corresponding to a ≤15% probability of CTCAE grade 3 or higher hyperbilirubinemia (in the absence of disease progression) to be calculated. Total bilirubin will be recorded and graded according to CTCAE version 4.02. All dose-related SAEs at 3 months follow-up will be followed until resolution, death or lost-to-follow-up. AEs related to disease progression will not be considered related to TheraSphere.
Stanford is currently accepting patients for this trial.
Boston Scientific Corporation
Collaborator: Biocompatibles UK Ltd
- Device: TheraSphere
- Up to 10 well defined unilobar/bilobar HCC tumor(s) per lobe with at least one tumor
≥3 cm ± PVT
- Liver dominant disease (limited extra-hepatic metastases in the lung and/or lymph
nodes are permitted (up to 5 lesions in the lung, with each individual lesion ≤2cm;
any number of lymph node lesions with each individual lesion ≤2 cm).
- Child Pugh stage A or B7.
- BCLC A, B or C.
- Must be male or female, 18 years of age or older.
- Bilirubin ≤2 mg/dL.
- Tumor replacement <50% of total liver volume assessed by diagnostic imaging consisting
of multi-phase contrast enhanced CT or contrast enhanced MRI.
- Diagnostic imaging consisting of multi-phase contrast enhanced CT or contrast enhanced
MRI within 3 months prior to TheraSphere® administration.
- Infusion of 99mTc-MAA in a single arterial location sufficient to cover up to 10
well-defined tumors per lobe ≤ 6 weeks prior to TheraSphere® administration.
- Patients must have received TheraSphere® in a single treatment setting in one or more
arterial locations sufficient to cover up to 10 well-defined tumors based on
angiography. Subsequent TheraSphere® treatment to the second lobe may occur at least 4
weeks following the initial TheraSphere® treatment.
- For patients receiving a second TheraSphere® treatment bilirubin levels must have been
recorded prior to the second treatment
- Patients must have had clinical evaluation (assessment of liver specific AEs) and
laboratory evaluation (at least a serum bilirubin level) at baseline.
- Tumor(s), ≥3 cm, measurable by mRECIST and RECIST 1.1 at baseline
- Prior external beam radiation treatment to the liver.
- Prior loco-regional liver directed therapy (cTACE, DEB-TACE and SIR-Spheres).
- Prior liver transplantation.
- Whole liver TheraSphere® treatment following prior liver resection.
- TheraSphere administration to ≤2 segments (e.g., radiation segmentectomy).
- Additional active therapy (TACE and treatment with SIR-Spheres) between first
TheraSphere treatment and 3 month (90 days) imaging.
- Hepatic vein invasion.
- Diagnosis of disease progression at peri-procedural imaging as compared to the
baseline imaging (physician's discretion).
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study